To better understand the biological processes by which METH and HIV disease confer risk for adverse cardiovascular, cerebrovascular, and cognitive outcomes, and whether cannabis might exert an ameliorative influence, we analyzed plasma markers linked to vascular disorders underlying inflammation such as CXL10/IP-10, CCL2/MCP-1, VCAM-1, and ICAM-1 in people with and without METH use disorder (MUD), past-month cannabis use, and HIV. Here, CCL2 is linked to vascular disorder.